The incretin response after successful islet transplantation

Transplantation

Volumn 97, Issue 2, 2014, Pages

  Vethakkan, Shireene R ^a   Walters, Jacqueline M ^b   Gooley, Judith L ^b   Boston, Raymond C ^c   Kay, Thomas W H ^d   Goodman, David J ^e   Jenkins, Alicia J ^b   Ward, Glenn M ^e  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e St Vincent's Health ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; INCRETINS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MIDDLE AGED;

EID: 84893495146     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000437565.15965.67     Document Type: Letter

References (16)

1. Nauck MA, Busing M, Orskov C, et al. Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation. Acta Diabetol 1993; 30: 39.
2. Holst JJ, Gromada J. Role of the incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol EndocrinolMetab 2004; 287: E199.
3. Holst JJ. The physiology of glucagon-like peptide. Physiol Rev 2007; 87: 1409.
4. Ghofalili KA, Fung M, Ao Z, et al. Effect of exenatide on A-cell function after islet transplantation in type 1 diabetes. Transplantation 2007; 83: 24.
5. Gangemi A, Salehi P, Hatipoglu B, et al. Islet transplantation for brittle type 1 diabetes: The UIC protocol. Am J Transplant 2008; 8: 1250.
6. Froud F, Faradji RN, Pileggi A, et al. The use of exenatide in islet transplant recipients with chronic allograftdysfunction: Safety, efficacy, and metabolic effects. Transplantation 2008; 86: 36.
7. Faradji RN, Tharavanij T, Messinger S, et al. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept. Transplantation 2008; 86: 1658.
8. Rickels MR, Mueller R, Markmann JF, et al. The effect of glucagon-like peptide-1 on Aand -cell function in isolated islet and whole pancreas transplant recipients. J Clin Endocrinol Metab 2009; 94: 181.
9. Knop FK, Vilsboll T, Madsbad S, et al. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007; 50: 797.
10. Meier JJ, Hong-McAtee I, Galasso R, et al. Intrahepatic transplanted islets in humans secrete insulin in a coordinate pulsatile manner directly into the liver. Diabetes 2006; 55: 2324.
11. Fritsche A, Stefan N, Hardt E, et al. Characterisation of beta-cell dysfunction of impaired glucose tolerance: Evidence for impairment of incretin-induced insulin secretion. Diabetologia 2000; 43: 852.
12. Hojberg PV, Zander M, Vilsboll T, et al. Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucoseinduced insulin secretion in patients with type 2 diabetes. Diabetologia 2008; 51: 632.
13. Fung M, ThompsonD, ShapiroRJ, et al. Effect of glucagon-like peptide-1(7-37) on beta-cell function after islet transplantation in type 1 diabetes. Diabetes Res Clin Pract 2006; 74: 189.
14. Jansson L, Carlsson P-O. Graft vascular function after transplantation of pancreatic islets. Diabetologia 2002; 45: 749.
15. Lau J, Jansson L, Carlsson P-O. Islets transplanted intraportally into the liver are stimulated to insulin and glucagon release exclusively through the hepatic artery. Am J Transplant 2006; 6: 967.
16. Vethakkan SR, Jenkins AJ, Kay TWH, et al. Improved second phase insulin secretion and preserved insulin sensitivity after islet transplantation. Transplantation 2010; 89: 1291.